Summary:
- The U.S. Food and Drug Administration (FDA) has approved a new drug called MYQORZO (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy.
- Hypertrophic cardiomyopathy is a genetic condition that causes the heart muscle to thicken, making it harder for the heart to pump blood effectively.
- MYQORZO is designed to improve the functional capacity and symptoms of patients with this condition, helping them to feel better and be able to do more physical activities.